NEW YORK, May 27- Drugmakers are renewing efforts to develop medicines to fight emerging antibiotic-resistant bacteria, but creating new classes of drugs on the scale needed is unlikely to happen without new financial incentives to make the effort worth the investment, companies and industry experts said. "The return on investment based on the current... » Read More
Dr. Steven Nissen, the cardiology chief at the Cleveland Clinic, reportedly remains on the shortlist to possibly become the next FDA Commissioner. Some analysts believe if Dr. Nissen gets the nod there could be a negative knee-jerk reaction in the big pharma sector stocks.
1st paragraph of story should go here
Dow component and giant healthcare company--you really can't lump it in with big pharma because it sells drugs, medical devices and consumer products--Johnson & Johnson reported earnings this morning.
The JPMorgan Healthcare Conference typically frontloads the conference putting most, if not all, of the heavy hitters' presentations in the first couple of days of the four-day event. So, it's no surprise that a company the size of Dendreon was pulling up the rear. But that doesn't mean there wasn't any news.
Even though it's one of the leading causes of cancer death in the U.S., pancreatic normally doesn't get much attention.
Paul Noglows, director of research at Lazard Capital Markets, suggested four stock picks in four different sectors that will see growth over the year.
I couldn't go to the formal, scripted Genentech presentation at the JPMorgan Healthcare Conference yesterday afternoon because I was busy doing the crazy interview on "Fast Money" with the CEO of athenahealth, Jonathan Bush. I've never done a CEO interview like it.
During his lunchtime keynote speech here at the JPMorgan Healthcare Conference JPM Chairman and CEO Jamie Dimon was asked to give his worst-case scenario for the economy. He said that'd be a 1982-type recession lasting about two years and with unemployment "North of 10 percent." Dimon said it would be "Irrational to not be prepared for that."
Not surprisingly it was standing room only in the grand ballroom of the Westin St. Francis Hotel in San Francisco for the Roche presentation this morning at the JPMorgan Healthcare Conference.
I'm covering the 27th Annual JPMorgan Healthcare Conference in San Francisco where I suspect there will be a big crowd for the Roche presentation later this morning. It's being reported that the Swiss drugmaker may soon raise its bid for Genentech. I'll be shocked if Roche says much about it either in the formal presentation or breakout session. But I'll be there just in case.
There's a method behind his Mad Money picks. Here's how you put that strategy to work yourself.
The FDA giveth and the FDA taketh away. Yesterday the agency handed Merck a little bit of a break with what could be interpreted as an endorsement, of sorts. But then this morning the FDA issued another delay in deciding whether to approve the company's Gardasil vaccine.
Within about a 12-hour period, two healthcare companies have blamed the pullback in hospital spending for worse-than-anticipated financial results.
That this stock does well during recessions is just one of many reasons it's a Mad Money favorite.
Don't look now, but in the first week of the new year shares of Elan stock lost nearly three-quarters of its value last year on safety concerns about the multiple sclerosis drug Tysabri, which it shares with Biogen Idec, and efficacy concerns over the Alzheimer's drug it's developing with Wyeth.
We all make mistakes. Gosh knows I've made more than a few. And a part of me hesitates to call attention to this one. I mean, you know what they say about paybacks and karma. But this one is too good a doozy to let pass.
The "Financial Times" apparently got a one-on-one interview with Pfizer Chairman and CEO Jeff Kindler and is playing up what he said with the headline, "Pfizer eyes merger deal with large rival."
As we head into the holiday break and the bloggable newsflow slows to a trickle, I am digging into the overflowing mailbag while filling in for my vacationing colleague Scott Wapner at the Nasdaq this week.
Drug pricing pressure under a Democratic administration be darned. $75,000. That's not a salary figure. That's the price one biotech analyst says Vertex Pharmaceuticals and its partner Johnson & Johnson might be able to charge--possibly even more--for their Hepatitis C drug.
We finished the day down, but these two guys were responsible for much of the trading session’s strength, Cramer says.